Wyeth dumps once-promising Curis collaboration

Back in 2004, Wyeth considered a project with Curis to develop small molecule and protein Hedgehog agonists--which promised new therapies for stroke and cardiovascular ailments--worth potentially more than $170 million in milestone payments.

That was then.

This morning, Curis announced that Wyeth is pulling out of the pact. "Our speculation is that Wyeth has decided to re-prioritize," a Curis spokesman told the Boston Globe. Curis pocketed a $3 million upfront payment in the Wyeth deal. Since then, Curis has repositioned itself as well, focusing on new cancer therapies.

- see this release from Curis
- read the story in the Boston Globe

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.